Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260690 | 0.98 | KEAP1 (0.33) | ALDH1A1EPHX1KEAP1NFE2L2 | |
| SCHEMBL29889579 | 0.75 | KEAP1 (0.35) | EPHX1KEAP1NFE2L2SSTR4 | |
| SCHEMBL4310017 | 0.74 | ALDH1A1 (0.39) | ALDH1A1SSTR4 | |
| SCHEMBL9795387 | 0.74 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8196191 | 0.74 | KEAP1 (0.33) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL4209005 | 0.71 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL10790172 | 0.71 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1876976 | 0.69 | EPHX1 (0.39) | ALDH1A1EPHX1KEAP1NFE2L2SSTR4 | |
| SCHEMBL29122810 | 0.69 | EPHX1 (0.39) | ALDH1A1EPHX1KEAP1NFE2L2SSTR4 | |
| SCHEMBL2895430 | 0.69 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | ALDH1A1 1039/4885EPHX1 1536/4885KEAP1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.